Koji Haratani, Bruce Reinhold, Jonathan S Duke-Cohan, Caroline G Fahey, Kemin Tan, Robert J Mallis, Alexander Gusev, Kenneth L Kehl, Jia Luo, Allyson Karmazyn, Elizabeth L Holliday, Daniel J Masi, Katarzyna J Zienkiewicz, Connor J Hennessey, Rafael B Blasco, Tran C Thai, Grace M Gibbons, Sophie Kivlehan, Patrick Lizotte, Cloud P Paweletz, Andrew J Aguirre, Keith L Ligon, Roberto Chiarle, Matthew J Lang, David A Barbie, Ellis L Reinherz
TP53 mutations occur early in malignant transformation as truncal events in tumor evolution and are therefore generally present in all descendant tumor cells, creating an immunological vulnerability. Here, we examined the immunogenicity and antigenicity of p53 neoantigens emerging from these truncal mutations. Comprehensive immunopeptidomics revealed that hotspot mutations in human tumors preferentially localize to p53 regions resistant to antigen processing, thereby avoiding display altogether. Moreover, for neoantigens presentable by HLA-A∗02:01 or HLA-B∗07:02 and structurally divergent from corresponding wild-type p53 peptide-HLA complexes, clinical tumors commonly lacked the relevant presenting HLA allele. Tumor cells further resisted T cell killing through increased activity of the aminopeptidase ERAP1, preventing display of high-affinity HLA-A∗02:01 complexes containing an immunogenic p53I195F-derived 11-mer, or by expressing low-affinity HLA-A∗02:01 complexes containing a p53R175H-derived 9-mer with poor antigenicity despite high-quality human TCRs. These findings define mechanisms by which tumors restrict targetable truncal neoantigen display and suggest immunopeptidome shift strategies to circumvent immune escape.